Covid-19 | Page 34 of 100 | Links Medicus Content Curation & Alerts in Medicine

Is it risky to sing in a choir or eat in a small restaurant? How much difference does it make if I open windows or clean surfaces?

A new #BMJInfographic helps people decide what to do in everyday situations to protect themselves, and others, from covid-19 https://t.co/RMoEwZ9wTz pic.twitter.com/XV9ElCoOGa

— The BMJ (@bmj_latest) December 2, 2021

Omicron is supercharging the COVID vaccine booster debate – “The data are growing that booster jabs enhance protection — but their durability, impact and ability to quash the new variant are unknown”.

3 Dec, 2021 | 10:19h | UTC

Omicron is supercharging the COVID vaccine booster debate – Nature

Omicron-variant border bans ignore the evidence, say scientists – “Researchers say travel restrictions in response to the newly detected coronavirus variant come too late and could even slow studies of Omicron”.

3 Dec, 2021 | 10:20h | UTC

Omicron-variant border bans ignore the evidence, say scientists – Nature

How bad is Omicron? What scientists know so far.

3 Dec, 2021 | 10:18h | UTC

How bad is Omicron? What scientists know so far – Nature

Opinion | Omg, Omicron! Why it’s too soon to panic about COVID vaccines and the new variant.

3 Dec, 2021 | 10:16h | UTC

Omg, Omicron! Why it’s too soon to panic about COVID vaccines and the new variant – The Conversation

Germany on Thursday announced a nationwide lockdown for the unvaccinated.

3 Dec, 2021 | 10:14h | UTC

Germany locks down unvaccinated people, as leaders plan to make shots compulsory – CNN

The Omicron Variant Is a Mystery. Here’s How Science Will Solve It – “So far, panic about the new Covid variant has outpaced actual information. Here’s what scientists around the world are trying to uncover”.

2 Dec, 2021 | 10:08h | UTC

The Omicron Variant Is a Mystery. Here’s How Science Will Solve It – Wired

See also the latest articles on the subject:

Where did ‘weird’ Omicron come from? – Science

We can prevail over Omicron. We just need to use the tools we have – The Guardian

How South African Researchers Identified the Omicron Variant of COVID – The New Yorker

The omicron variant has been found in 23 countries – NPR

These countries have found cases of the Omicron Covid-19 variant so far – CNN

Scientists say it will take weeks to tell how dangerous Omicron really is. Here’s why – CNN

Coronavirus variants: Here’s what we know – CNN

To catch variants like omicron, the world needs to sequence way more virus genes – Vox

Omicron’s Best- and Worst-Case Scenarios – The Atlantic

Africa: tackle HIV and COVID-19 together – Nature

Omicron Travel Bans Violate International Health Rules and Decimate Southern Africa’s Fragile Tourism Industry – Health Policy Watch

The mystery of where omicron came from — and why it matters – NPR

A reason for optimism on Omicron: Our immune systems are not blank slates – STAT

Omicron – Science-Based Medicine

Covid: Omicron may require ‘very stringent response’, say Sage scientists – BBC

WHO warns against Omicron travel bans as nations shut borders – MedicalXpress

Israeli doctor believes he caught Omicron variant of Covid in London – The Guardian

First case of Omicron coronavirus variant identified in the U.S. – STAT

Retrospective Cohort Study: Except for Rituximab, most immunosuppressive medicines were not associated with increased risk of mechanical ventilation or death in patients hospitalized with Covid-19.

2 Dec, 2021 | 10:07h | UTC

Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative – The Lancet Rheumatology

Commentaries:

What does endemic COVID-19 mean for the future of rituximab? – The Lancet Rheumatology

Outcomes for hospitalized COVID-19 patients taking immunosuppressive medications similar to non-immunosuppressed patients, study finds – Johns Hopkins University Bloomberg School of Public Health

Study: Immune-suppressed not at higher risk of poor COVID outcomes – CIDRAP

Commentary on Twitter

NEW RESEARCH—Long-term use of immunosuppressive medicines and in-hospital #COVID19 outcomes: data from N3C shows no increased risk of mechanical ventilation or in-hospital death with the exception of #rituximab https://t.co/vEyTzfvK5q #LancetRheumatology
@JohnsHopkins pic.twitter.com/NqlttjGrpj

— The Lancet Rheumatology (@TheLancetRheum) November 16, 2021

Systematic Review: Models of COVID-19 vaccine prioritization – “for countries seeking to minimize deaths, prioritizing vaccination of senior adults was the optimal strategy and for countries seeking to minimize cases the young were prioritized”.

2 Dec, 2021 | 10:02h | UTC

Models of COVID-19 vaccine prioritisation: a systematic literature search and narrative review – BMC Medicine

World Health Assembly agrees to launch process to develop historic global accord on pandemic prevention, preparedness and response.

2 Dec, 2021 | 10:03h | UTC

World Health Assembly agrees to launch process to develop historic global accord on pandemic prevention, preparedness and response – World Health Organization

Commentary: Standing Ovation as WHO Member States Commit to Negotiating New Pandemic Accord – Health Policy Watch

Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.

2 Dec, 2021 | 10:04h | UTC

Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence – Drugs

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

Complete countrywide mortality in COVID patients receiving ECMO in Germany throughout the first three waves of the pandemic.

1 Dec, 2021 | 09:52h | UTC

Complete countrywide mortality in COVID patients receiving ECMO in Germany throughout the first three waves of the pandemic – Critical Care

WHO advice for international traffic in relation to the SARS-CoV-2 Omicron variant (B.1.1.529).

1 Dec, 2021 | 10:02h | UTC

WHO advice for international traffic in relation to the SARS-CoV-2 Omicron variant (B.1.1.529) – World Health Organization

Commentary: Over-60s, vulnerable should postpone travel due to Omicron: WHO – MedicalXpress

See also the latest articles on the subject:

Will omicron – the new coronavirus variant of concern – be more contagious than delta? A virus evolution expert explains what researchers know and what they don’t – The Conversation

WHO pleads for ‘rational’ Omicron response – MedicalXpress

Omicron: WHO warns of ‘high infection risk’ around globe – BBC

Video: Why Omicron is the most worrying Covid variant yet – video explainer – The Guardian

Doctors hope Omicron causes milder cases of Covid — but it’s still too early to say – STAT

Doctor: Many South Africans ill in surge have mild symptoms – Associated Press

New Findings Show the Omicron Variant Spread Widely At a Faster Pace Than Initially Thought – TIME

Why some researchers think the omicron variant could be the most infectious one yet – NPR

Omicron Covid variant ‘present in Europe at least 10 days ago’ – The Guardian

Netherlands says Omicron variant was already in country earlier than previously thought – CNN

Netherlands detections hint at earlier Omicron spread – CIDRAP

Epidemiologist awaits clearer picture on omicron – Harvard University

Pfizer research head envisions a sprint to develop Omicron vaccine, if it’s needed – STAT

Omicron COVID variant was in Europe before South African scientists detected and flagged it to the world – CBS News

Moderna boss predicts current vaccines may be less effective against Omicron – The Guardian

Wealthy nations starved the developing world of vaccines. Omicron shows the cost of this greed – The Conversation

Travel restrictions by country following the Omicron variant outbreak – CNN

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

1 Dec, 2021 | 09:56h | UTC

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID – STAT

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Ending the COVID-19 Pandemic Hinges on Trust: Science alone won’t pull us out of the pandemic.

1 Dec, 2021 | 09:47h | UTC

Ending the COVID-19 Pandemic Hinges on Trust – Think Global Health

Commentary on Twitter

Despite the availability of effective vaccines, deaths from #COVID in 2021 are two-thirds greater than the # of COVID-related deaths in 2020. @TomBollyky & @IHME_UW's Chris Troeger say trust—and the lack of it—has played a crucial role in the pandemic.https://t.co/8NiItD1wdc

— Think Global Health (@ThinkGlobalHlth) November 30, 2021

Using wearable data, a real-time alerting system can be used for the early detection of Covid-19 and other stress events.

1 Dec, 2021 | 09:59h | UTC

Real-time alerting system for COVID-19 and other stress events using wearable data – Nature Medicine

Commentary: Scientists develop a smartwatch-based device for early detection of COVID-19 – News Medical

Commentary on Twitter

A study in @NatureMedicine shows that a smartwatch-based alerting system was able to detect pre-symptomatic and asymptomatic SARS-CoV-2 infection in a high percentage of cases. https://t.co/tquzpYa4pV pic.twitter.com/VIq3phKZ7J

— Nature Portfolio (@NaturePortfolio) November 30, 2021

Another randomized trial showed convalescent plasma does not benefit patients hospitalized with Covid-19.

1 Dec, 2021 | 09:49h | UTC

Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial – JAMA Network Open

M-A: Convalescent plasma does not reduce mortality in COVID-19.

RCT: Another study shows convalescent plasma does not improve outcomes in critically ill patients with Covid-19.

RCT: Convalescent plasma does not improve outcomes and may be harmful to hospitalized patients with COVID-19.

NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms.

M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

Commentary on Twitter

The TSUNAMI RCT showed that high-titer convalescent plasma (CP) did not reduce the risk of severe respiratory failure or death in hospitalized patients with #COVID19 pneumonia. https://t.co/4q0S2AtfMj

— JAMA Network Open (@JAMANetworkOpen) November 29, 2021

Guidelines developed under pressure. The case of the COVID-19 low-quality “rapid” guidelines and potential solutions.

1 Dec, 2021 | 08:54h | UTC

Guidelines developed under pressure. The case of the COVID-19 low-quality “rapid” guidelines and potential solutions – Journal of Clinical Epidemiology

Cohort study: Allergic conditions linked to lower COVID-19 infection risk.

1 Dec, 2021 | 08:52h | UTC

News Release: Allergic conditions linked to lower COVID-19 infection risk – BMJ

Original Study: Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK) – Thorax

WHO Technical Brief and Priority Actions: Enhancing Readiness for Omicron.

30 Nov, 2021 | 08:46h | UTC

Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States – World Health Organization

Commentaries:

The World Health Organization warns of very high risk posed by the omicron variant – NPR

Omicron Covid variant poses very high global risk, says WHO – The Guardian

See also the latest articles on the subject:

Statement On Omicron Variant – Infectious Diseases Society of America

Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear – The BMJ

Helen Salisbury: Omicron—panic mongering or appropriate caution? – The BMJ

The Omicron variant underscores the global stakes of Covid-19 vaccine inequity – STAT

EXPLAINER: What we know and don’t know about omicron variant – Associated Press

Omicron: How do you detect it? – BBC

Are new COVID variants like Omicron linked to low vaccine coverage? Here’s what the science says – The Conversation

Omicron: why the WHO designated it a variant of concern – The Conversation

It looks like Omicron causes milder illness – is this how COVID becomes endemic? – The Conversation

As Omicron spreads, studies suggest that travel bans alone don’t do much good – NPR

RCT: SARS-CoV-2 transmission was largely prevented through a comprehensive preventive intervention in a large, live, indoor gathering event.

30 Nov, 2021 | 08:43h | UTC

Prevention of SARS-CoV-2 transmission during a large, live, indoor gathering (SPRING): a non-inferiority, randomised, controlled trial – The Lancet Infectious Diseases

Invited Commentary: Concerts and COVID: can the beat go on? – The Lancet Infectious Diseases

Commentary on Twitter

SPRING :a non-inferiority, randomised, controlled trial 🇫🇷
In an indoor arena w/o physical distancing in which the audience tested negative,showed high compliance with medical mask wearing, and ventilation was optimised, transmission of SARS-CoV-2 was rarehttps://t.co/OfmJTeJsDb

— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) November 27, 2021

New research Article: Prevention of #SARSCoV2 transmission during a large, live, indoor gathering (SPRING): a non-inferiority, randomised, controlled trial https://t.co/gClVGsa3l9 pic.twitter.com/3aYaLVR3Jr

— The Lancet Infectious Diseases (@TheLancetInfDis) November 28, 2021

Preliminary RCT found prostacyclin may improve outcomes in mechanically ventilated patients with COVID-19 and severe endotheliopathy.

30 Nov, 2021 | 08:42h | UTC

Prostacyclin in Mechanically Ventilated Patients with COVID-19 and Severe Endotheliopathy: A Multicenter, Randomized, Clinical Trial – American Journal of Respiratory and Critical Care Medicine

News release: Well-known drug could help the most severely affected COVID-19 patients in intensive-care departments – by University of Copenhagen

Commentary from the author on Twitter (thread – click for more)

Our RCT on endothelial rescue (COMBAT COVID19) is out: Prostacyclin in Mechanically Ventilated Patients with COVID-19 and Severe Endotheliopathy (COMBAT COVID19). https://t.co/dkvQIP4hP3 @ATSBlueEditor 1/6

— Jakob Stensballe (@J_Stensballe) November 24, 2021

Electrocardiogram monitoring in the prone position in Covid-19 acute respiratory distress syndrome.

30 Nov, 2021 | 08:38h | UTC

Electrocardiogram monitoring in the prone position in coronavirus disease 2019 acute respiratory distress syndrome – European Journal of Cardiovascular Nursing

Commentary on Twitter

Prone position alters #ECG in patients with #COVID19 ARDS. Read this short report from #EJCN: https://t.co/ySbIsS0Abf @escardio @ACNAPPresident @EditorEJCN #ACNAP @LeonieKlompstra #cardiotwitter pic.twitter.com/1GxEZB2Cpf

— European Society of Cardiology Journals (@ESC_Journals) November 27, 2021

Stay Updated in Your Specialty